MyFinsight
Home
Blog
About
Cash and cash
equivalents
$136,040K
(11.92%↑ Y/Y)
Collaboration and license
agreement receivable
$6,000K
Prepaid expenses and
other current assets
$3,428K
(58.34%↑ Y/Y)
Property and equipment
$12,768K
(5.18%↑ Y/Y)
Total current assets
$145,468K
(17.58%↑ Y/Y)
Operating lease
right-of-use asset
$3,608K
(-15.80%↓ Y/Y)
Property and equipment,
net
$3,359K
(-16.40%↓ Y/Y)
Restricted cash
$1,819K
(1.39%↑ Y/Y)
Less accumulated
depreciation
$9,409K
(15.86%↑ Y/Y)
Total assets
$154,254K
(15.28%↑ Y/Y)
Total liabilities and
stockholders' equity
$154,254K
(15.28%↑ Y/Y)
Total liabilities
$81,990K
(-35.31%↓ Y/Y)
Total stockholders'
equity
$72,264K
(922.27%↑ Y/Y)
Accumulated deficit
-$434,691K
(-5.29%↓ Y/Y)
Total current
liabilities
$34,198K
(-35.79%↓ Y/Y)
Common stock warrant
liabilities
$30,200K
(-21.66%↓ Y/Y)
Deferred revenue, net of
current portion
$12,715K
(-55.59%↓ Y/Y)
Operating lease
liability, net of current...
$4,877K
(-22.61%↓ Y/Y)
Additional paid-in capital
$506,954K
(20.72%↑ Y/Y)
Common stock, 0.0001
par value...
$1K
(-80.00%↓ Y/Y)
Deferred revenue,
current portion
$22,603K
(-46.54%↓ Y/Y)
Accrued expenses
$7,854K
(39.73%↑ Y/Y)
Accounts payable
$2,315K
(-43.50%↓ Y/Y)
Operating lease
liability, current portion
$1,426K
(12.82%↑ Y/Y)
Back
Back
Balance Sheet
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)
source: myfinsight.com